The Global Epilepsy Drugs Market is expected to reach $10.3 Billion at a CAGR rate of 5.46% by 2027, according to Renub Research, a market research and consulting company.
Worldwide, millions of people are affected by neurological disorders and epilepsy is one of them, affecting people of all ages.
Epilepsy is a central nervous system disorder in which brain activity becomes abnormal, causing seizures or periods of unusual behavior, sensations, and sometimes loss of awareness, according to Mayo Clinic.
The World Health Organization (WHO) says epilepsy affects around 50 million people across the world and about 2.4 million new cases are diagnosed every year.
The United States is the largest epilepsy drug market due to better healthcare infrastructure and rising cases of epilepsy, according to Medgadget.
The Epilepsy Foundation of Michigan says epilepsy is the fourth most common neurological disorder in the United States. And about 1% of Americans have some form of epilepsy. Also, there is a rising demand for epilepsy drugs in the nation.
In addition, countries such as China, Brazil, and India have a higher incidence of the neurological condition, requiring better treatment options.
All of these indicate that the global epilepsy drug market has the potential to grow in the near future. The market is likely to grow at a CAGR of 5.46% between 2020 and 2027, according to Renub Research.
As far as epilepsy drugs are concerned, the market is segmented into first-generation, second-generation, third-generation, and others. The third-generation holds the largest share because drugs such as lacosamide (Vimpat), brivaracetam (Briviact), and others have penetrated the market. Plus, the drugs have proven to be quite effective in treating epilepsy.
The second-generation antiepileptic drug class, such as levetiracetam (Keppra) and perampanel (Fycompa), are also dominating the market due to their safety and tolerability.
Some of the key players involved in the global epilepsy drug market include Eisai Co., Ltd., UCB Inc., H. Lundbeck A/S, and GW Pharmaceuticals Plc.
The market report is available on Renub Research’s website. The company has over 10 years of experience in international business-to-business researches, surveys, and consulting. The article first appeared on Medgadget.
